glp 1 approved for cardiovascular disease A new Science Perspective highlights the growing body of evidence that hints at the potential of GLP-1–based medications in treating conditions other than diabetes and obesity, including and neurodegenerative disorders Heart Benefits of GLP-1s Disappear

Cellular longevity slowing processes of aging and cellular senescence

Mental fatigue is more subtle

Combining GLP-1 medications with resistance training and adequate protein intake partially mitigates but does not eliminate muscle loss

Here in the States, Wegovy manufacturer Novo Nordisk has filed for FDA approval of its injection to 7.2 mg and been approved as of March 19, 2026

More specifically, receptors levels in the frontal and temporal cortex were reduced by approximately 50% of control values in AD patients while a 40% reduction was reported in the hippocampus and no significant changes were found in the cingulate cortex, postcentral gyrus, temporal pole, and superior temporal gyrus